Novartis AG
CRYSTALLINE FORMS OF A TRIAZOLOPYRIMIDINE COMPOUND

Last updated:

Abstract:

Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

Status:
Application
Type:

Utility

Filling date:

9 Jul 2021

Issue date:

4 Nov 2021